XML 65 R53.htm IDEA: XBRL DOCUMENT v3.20.2
Collaborations and Licensing Arrangements - Additional Information (Detail) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
May 31, 2018
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Dec. 31, 2018
Dec. 31, 2019
Sep. 30, 2019
Oct. 31, 2018
Sep. 30, 2018
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Deferred revenue — current   $ 32,184,000   $ 32,184,000     $ 32,503,000      
Deferred revenue — long term   4,860,000   4,860,000     $ 8,344,000      
Revenue' collaborations and services   15,114,000 $ 15,002,000 31,349,000 $ 32,450,000          
AFREZZA product sales                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Revenue' collaborations and services   6,985,000 6,065,000 14,985,000 11,141,000          
Collaboration and License Agreement | Receptor CLA                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Deferred revenue — current   100,000   100,000            
Collaboration and License Agreement | United Therapeutics Corporation                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Upfront payment received                 $ 45,000,000.0  
Milestone Payment Received   12,500,000                
Potential milestone payments to be receive   12,500,000   12,500,000            
Total transaction price   101,400,000   101,400,000            
Deferred revenue   35,000,000.0   35,000,000.0            
Deferred revenue — current   31,900,000   31,900,000            
Deferred revenue — long term   3,100,000   3,100,000            
Collaboration and License Agreement | United Therapeutics Corporation | Maximum                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Additional option exercise and development milestone payments to be receive   40,000,000.0   40,000,000.0            
Research Agreement | United Therapeutics Corporation                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Upfront payment received                   $ 10,000,000.0
Total transaction price   10,000,000.0   10,000,000.0            
Research Agreement | United Therapeutics Corporation | Product Prototype                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Total transaction price   9,000,000.0   $ 9,000,000.0            
Revenue performance obligation, method used       The revenue for the product prototype was recognized using an output method (based on project milestones achieved and surveys of performance completed to date). The Company believed that this method best reflected the measure of progress toward complete satisfaction of the performance obligation.            
Research Agreement | United Therapeutics Corporation | Engineering Consulting Services                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Total transaction price   1,000,000.0   $ 1,000,000.0            
Revenue performance obligation, method used       The revenue for the engineering consulting services was recognized using a ratable method until the obligation was satisfied. The Company believed that this method best reflected the measure of progress toward complete satisfaction of the performance obligation.            
Research Agreement | United Therapeutics Corporation | Maximum                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Potential milestone payments to be receive               $ 30,000,000.0    
Supply and Distribution Agreement | AFREZZA product sales | Biomm                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Revenue' collaborations and services   200,000 $ 0 $ 200,000 $ 0          
License and Distribution Agreement | Foreign Country | India Tax Authority                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Income Taxes Paid           $ 200,000        
License and Distribution Agreement | Cipla Distribution Agreement                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Deferred revenue   1,900,000   1,900,000            
Deferred revenue — current   200,000   200,000            
Deferred revenue — long term   $ 1,700   $ 1,700            
Marketing and distribution agreement date 2018-05